HBI-8000, also known as CS-055, is primarily investigated for its potential in cancer therapy. It functions as a histone deacetylase (HDAC) inhibitor, which plays a role in regulating gene expression and inducing apoptosis in cancer cells. This compound is being studied for its efficacy in treating various malignancies, including lymphoma and solid tumors. Its ability to modulate epigenetic mechanisms makes it a promising candidate for combination therapies, potentially enhancing the effectiveness of other anticancer drugs. Clinical trials are ongoing to evaluate its safety, tolerability, and therapeutic benefits in patients.